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Objectives. This study sought to investigate the effects of
tirofiban versus placebo on the incidence of adverse cardiac
outcomes and coronary artery restenosis at 6 months.
Background. Tirofiban is a highly selective, short-acting inhib-
itor of fibrinogen binding to platelet glycoprotein IIb/IIIa. In a
recent clinical study, tirofiban reduced the incidence of adverse
cardiovascular events at both 2 and 7 days after coronary angio-
plasty or directional coronary atherectomy. This reduction per-
sisted but was no longer statistically significant at 30 days.
Methods. The Randomized Efficacy Study of Tirofiban for
Outcomes and Restenosis (RESTORE) trial was a randomized,
double-blind, placebo-controlled trial of tirofiban in patients
undergoing balloon angioplasty or directional atherectomy within
72 h of presentation with either unstable angina pectoris or acute
myocardial infarction. All patients received an initial bolus
(10 mg/kg body weight over 3 min), followed by a 36-h infusion
(0.15 mg/kg per min) of either tirofiban or placebo.
Results. At 6 months the composite end point (either death
from any cause, new myocardial infarction, bypass surgery for
angioplasty failure or recurrent ischemia, repeat target vessel
angioplasty or stent insertion for actual or threatened abrupt
closure) occurred in 1,070 placebo group patients (27.1%) and
1,071 tirofiban group patients (24.1%, p 5 0.11). Analysis of
6-month coronary arteriograms by means of quantitative coronary
arteriography showed no significant difference between placebo-
and tirofiban-treated patients in either the incidence of a >250%
diameter stenosis (57% vs. 51%, p 5 NS), a loss of >250% of lumen
diameter gained (50% vs. 50%, p 5 NS) or a loss of >20.72 mm of
lumen diameter (44% vs. 42%, p 5 NS).
Conclusions. The 3% absolute reduction in the incidence of the
composite end point at 6 months (27.1% placebo vs. 24.1%
tirofiban) was similar to that previously reported at 2 days (8.7%
vs. 5.4%, p < 0.005), and there does not appear to be any late effect
of tirofiban on clinical end points between day 2 and 6 months.
Tirofiban did not reduce the incidence of restenosis at 6 months
when defined in a number of ways.
(J Am Coll Cardiol 1998;32:28–34)
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Percutaneous coronary interventions expose many of the
highly thrombogenic contents of the arterial wall, and coronary
thrombosis remains a persistent problem after conventional
balloon angioplasty and directional coronary atherectomy
(DCA). Despite standard therapy with aspirin and heparin
(1,2), thrombotic occlusion after interventional procedures still
occurs in 4% to 12.8% of patients (3–5) and has prompted the
search for more effective antiplatelet agents (5–14).
In high risk patients undergoing percutaneous transluminal
coronary angioplasty (PTCA), the monoclonal antibody abcix-
imab, directed against the platelet glycoprotein (GP) integrin
receptor IIb/IIIa, has been shown to significantly reduce the
composite incidence of death, myocardial infarction, emer-
gency repeat angioplasty, emergency coronary artery bypass
graft surgery (CABG) or stent implantation by 35% at both 2
and 30 days (5,15–17). Tirofiban (Aggrastat, Merck & Co.) is a
synthetic, short-acting, highly selective nonpeptide inhibitor of
fibrinogen binding to platelet GP IIb/IIIa (18–22). Potential
advantages of this drug include a rapid onset of action, rapid
reversal of antiplatelet activity after drug discontinuation,
suitability for multiple repeat administrations and high speci-
ficity for the GP IIb/IIIa receptor.
The Randomized Efficacy Study of Tirofiban for Outcomes
and REstenosis (RESTORE) trial (23) was a randomized,
double-blind, placebo-controlled trial of tirofiban in patients
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undergoing PTCA or DCA within 72 h of presentation with
either unstable angina pectoris or acute myocardial infarction.
Previously, the RESTORE study group has reported (23) that
tirofiban compared with placebo reduced the incidence of the
composite end point of death; myocardial infarction; any target
vessel repeat PTCA or CABG for recurrent ischemia; and
stent implantation for abrupt closure by 38% at 2 days (p ,
0.005) and by 27% at 7 days (p 5 0.022) largely due to a
reduction in nonfatal myocardial infarction and the need for
repeat angioplasty. The primary composite end point at 30
days was reduced from 12.2% in the placebo group to 10.3% in
the tirofiban group, a 16% relative reduction (p 5 0.16). When
only repeat angioplasty and CABG performed on an urgent
(i.e., emergency) basis were included as components of the
30-day composite, the 10.5% event rate in the placebo group
was reduced to 8.0% in the tirofiban group, a 24% relative
reduction (p 5 0.052) (23). The incidence of bleeding and
thrombocytopenia did not differ significantly between
tirofiban- and placebo-treated patients.
The effect of tirofiban and other GP IIb/IIIa inhibitors on
angiographic restenosis is unknown. The goal of the 6-month
clinical and angiographic substudies was to investigate the
effects of tirofiban compared with placebo on the incidence of
adverse cardiac outcomes and on coronary artery restenosis as
measured by quantitative angiography.
Methods
RESTORE trial. The RESTORE trial (23) was a random-
ized, double-blind, placebo-controlled trial of tirofiban in
aspirin- and heparin-treated patients undergoing PTCA or
DCA within 72 h of presentation with acute coronary syn-
dromes (either unstable angina or an acute myocardial infarc-
tion). Unstable angina was defined as typical anginal pain at
rest or with minimal effort and either 1) electrocardiographic
changes; 2) hemodynamic changes suggestive of myocardial
ischemia; or 3) angiographic evidence of thrombus in the
target vessel immediately before PTCA or DCA (characterized
by a stenosis .70% with a hazy appearance, intraluminal filling
defect, overhanging edge, high degree of eccentricity or re-
duced Thrombolysis in Myocardial Infarction [TIMI] flow
grade). Acute myocardial infarction was defined as typical
ischemic pain lasting .20 min with ST-T wave changes or
pathologic Q waves and a serum creatine kinase elevation
greater than twice the upper limit of normal or an elevated
creatine kinase-MB fraction value.
Treatment and adjunctive medical therapy. Patients re-
ceived 300 to 325 mg of aspirin orally within 12 h of PTCA or
DCA. Guidelines for heparin administration during PTCA
were a maximal initial bolus of 10,000 U before the procedure
(weight adjusted to 150 U/kg for patients ,70 kg), and
intraprocedural heparin was administered as required to main-
tain an activated clotting time of 300 to 400 s. After the lesion
was crossed with the guide wire, the patient was randomized to
receive either a bolus of tirofiban (10 mg/kg body weight) or
placebo intravenously over 3 min. Each patient then received
an intravenous infusion of tirofiban (0.15 mg/kg per min) or
placebo for 36 h. Operators were urged to place intracoronary
stents only in urgent “bailout” situations (e.g., actual or
threatened abrupt closure). The decision to perform DCA or
PTCA was left to the discretion of the operator. Investigators
were advised to discontinue heparin administration at the
conclusion of the PTCA or DCA procedure and to remove
sheaths when the activated clotting time was ,180 s.
Coronary arteriographic substudy. Selected study sites en-
rolled all consecutive patients in the angiographic substudy
until a total of ;500 patients had been enrolled. At the
beginning of the PTCA or DCA procedure, nitroglycerin
(200 mg intracoronary) was administered into each coronary
artery (left and right coronary arteries) before repeat angiog-
raphy. At the completion of the procedure, nitroglycerin
(200 mg intracoronary) was readministered into each coronary
artery (left and right coronary arteries) before repeat angiog-
raphy. For the 6-month follow-up angiogram, the catheteriza-
tion laboratory, the equipment used, the procedure followed
(including angles and magnifications used) and the therapy
given were identical.
For the baseline preprocedural and postprocedural angio-
grams the angiographically “optimal” view (i.e., without vessel
overlapping or foreshortening) and the view orthogonal to it
were recorded on cine film at 4- to 5-in. magnification. When
two good views were not available, a single view was used that
showed the stenosis in its greatest severity without foreshort-
ening, motion blur or overlapping of branches. A portion of
the non–contrast-filled catheter shaft was visible during some
phase of the injection to allow for calibration and was centered
in the image field whenever possible to minimize the impact of
pincushion distortion.
Follow-up angiography was performed as close to 6 months
after the index procedure as possible; however, angiography
performed between 17 and 30 weeks after the initial PTCA or
DCA was accepted. If repeat cardiac catheterization was
necessary before the end of 16 weeks, and there was evidence
of restenosis, this early angiogram was used as the follow-up
angiogram and a repeat 6-month follow-up angiogram was not
necessary. However, if there was no evidence of restenosis,
angiography was repeated between 17 and 30 weeks. All
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follow-up angiography was completed before the end of study
week 30. Patients who underwent intracoronary stent place-
ment at the time of the initial procedure were not required to
return for coronary arteriography.
Quantitative angiography. All physicians and technicians
in the angiographic core laboratory were blinded to treatment
group assignment, the investigative center’s interpretation of
the angiogram and the clinical outcome of the patient. A
previously described and validated automated edge detection
algorithm was utilized for quantitative angiographic analysis
(24). Restenosis in the target culprit lesion was prospectively
defined as follows: 1) $50% diameter stenosis at the time of
follow-up angiography in those patients who had a ,50%
stenosis after the initial intervention; 2) late loss in minimal
lumen diameter $0.72 mm (25); 3) late loss $50% of the
initial gain in minimal lumen diameter. Flow before and after
PTCA was assessed according to both the conventional TIMI
flow grade classification scheme (26) and the corrected TIMI
frame count (27). Thrombus grade was assessed using the
standard TIMI definitions (28).
Clinical end points. The clinical end points of the study
were death from any cause; new myocardial infarction, CABG
for angioplasty failure or recurrent ischemia; repeat target
vessel revascularization for recurrent ischemia; implantation of
an intracoronary stent because of actual or threatened abrupt
closure of the target vessel; and a composite end point, which
was the occurrence of any of these events (23). End points
were evaluated at 2, 7 and 30 days, and at 6 months. The
prespecified primary hypothesis of the study was that tirofiban
would result in a reduction in the 30-day composite end point
compared with placebo (23). All end points were adjudicated
by an independent, blinded end point classification committee
according to previously reported definitions (23).
Statistical analysis. The statistical significance of the dif-
ferences between treatment groups with respect to the com-
posite end point and its components was assessed using logistic
regression analysis (PROC LOGISTIC, SAS) (29). The depen-
dent variable was an indicator for whether the patient experi-
enced the specific end point. The analysis was based on the
number of patients, not events; any patient experiencing one or
more of the composite events within the specific time periods
was counted as having a primary event. The independent
variables included an indicator of treatment group and the
following two covariates: inclusion criteria (unstable angina,
acute myocardial infarction within 3 days, acute myocardial
infarction treated with primary PTCA) and the primary pro-
cedure (DCA or PTCA). The incidence of restenosis was
assessed using chi-square analysis. All tests were two-sided,
and statistical significance was declared if p # 0.05. Cumulative
event rates over time were plotted using Kaplan-Meier curves.
Results
Patients. The trial included 2,212 randomized patients.
The study drug (tirofiban or placebo) was not administered in
71 patients (either because the angioplasty procedure was not
performed or the indication for angioplasty changed); there-
fore, a total of 2,141 patients received study drug infusion and
were included in the efficacy and safety analyses as prespecified
in the protocol (23). Of these patients, 619 (315 for the placebo
group, 314 for the tirofiban group) were enrolled in the
6-month angiographic restenosis substudy. Paired serial angio-
grams were available for 416 (67.2%) of these 619 patients
(205 for the placebo group, 211 for the tirofiban group).
Among tirofiban-treated patients, 1,057 (99%) of 1,071 were
available for 6 month follow-up, and among placebo patients,
1,050 (98%) of 1,070 were available.
Baseline characteristics. The baseline characteristics of all
patients included in the RESTORE trial have been previously
reported (23) and were similar between patients treated with
tirofiban or placebo. For patients in the 6-month angiographic
substudy, baseline clinical characteristics again did not differ
between the placebo and tirofiban groups (Table 1) and were
similar to those of patients in the overall trial. Fifty-nine
percent of substudy patients in the placebo group and 50.2% in
the tirofiban group had one diseased vessel, 25.9% and 32.7%
had two diseased vessels, and 11.2% and 15.2% had three
diseased vessels, respectively (p 5 NS for treatment group
difference). Unstable angina pectoris was the most common
inclusion criteria in the placebo (67.3%) and tirofiban (66.8%)
groups. The intervention was performed during acute myocar-
dial infarction (i.e., as primary angioplasty) in 2.0% of the
placebo group and 2.4% of the tirofiban group. The interven-
tion was performed as a nonprimary procedure within 3 days of
Table 1. Baseline Characteristics of Patients in RESTORE
Angiographic Substudy*
Placebo
Group
(n 5 205)
Tirofiban
Group
(n 5 212)
Mean age (yr) 58.8 59.9
Men 147 (72.4%) 156 (73.6%)
Risk factor
Diabetes mellitus 47 (22.9%) 43 (20.3%)
Hypertension 116 (56.6%) 117 (55.2%)
Elevated cholesterol 95 (46.3%) 104 (49.1%)
History of smoking 130 (63.4%) 122 (57.5%)
No. of diseased vessels
1 121 (59.0%) 106 (50.2%)
2 53 (25.9%) 69 (32.7%)
3 23 (11.2%) 32 (15.2%)
Qualifying event
Unstable angina 138 (67.3%) 141 (66.8%)
Acute MI
Nonprimary PTCA 63 (30.7%) 65 (30.8%)
Primary PTCA 4 (2.0%) 5 (2.4%)
Initial procedure performed
PTCA 189 (92.2%) 194 (91.9%)
DCA 16 (7.8%) 17 (8.1%)
*p 5 NS for all comparisons. Data presented are mean value or number (%)
of patients. DCA 5 directional coronary atherectomy; MI 5 myocardial
infarction; PTCA 5 percutaneous transluminal coronary angioplasty; RE-
STORE 5 Randomized Efficacy Study of Tirofiban for Outcomes and Resten-
osis.
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acute myocardial infarction in 30.7% of the placebo group and
30.8% of the tirofiban group. The initial procedure performed
was most frequently conventional PTCA (92.2% in the placebo
group, 91.9% in the tirofiban group), whereas DCA was
performed in the remainder of patients.
Clinical end points. The event rate for the occurrence of
the composite end point from the time of randomization
through 6 months for all patients is shown in Table 2. At 6
months, the composite end point occurred in 27.1% of
placebo-treated patients and 24.1% of tirofiban-treated pa-
tients (p 5 0.11). These same trends were observed in patients
treated both with conventional PTCA (267 [26.8%] of 997 vs.
237 [24.1%] of 985) and those treated with DCA (23 [31.5%]
of 73 vs. 21 [24.4%] of 86). The event rates for the individual
components of the composite end point are also shown in
Table 2. Except for death, all differences in the incidence of
end point components were in the same direction, favoring
tirofiban, but none was statistically significant. There was a
7.6% rate of acute myocardial infarction in the placebo group
versus a 6.3% rate of acute myocardial infarction in the
tirofiban group (p 5 0.22) and a 1.4% mortality rate in the
placebo group versus a 1.8% mortality rate in the tirofiban
group (p 5 0.49). Tirofiban did not significantly reduce the risk
of repeat angioplasty (15.7% for tirofiban vs. 17.1% for
placebo, p 5 0.38) or CABG procedures (5.5% for tirofiban vs.
6.8% for placebo, p 5 0.20).
Angiographic substudy. All baseline (before and after in-
tervention) angiographic lumen dimensions were similar in the
two groups (Table 3). The reference diameter for arteries was
2.70 6 0.57 mm for the placebo group and 2.77 6 0.74 mm for
the tirofiban group. Initial minimal lumen diameter was 0.54 6
0.33 mm for the placebo group and 0.57 6 0.39 mm for the
tirofiban group. The postprocedural minimum lumen diameter
was 1.89 6 0.48 mm for the placebo group and 1.89 6 0.56 mm
for the tirofiban group.
There was no difference between the placebo and tirofiban
groups in either the preinterventional CTFC (47.8 6 33.0 vs
52.0 6 34.5, respectively, p 5 NS) or the TIMI flow grade
distribution (41% TIMI grade 3 flow and 19% TIMI grade 0 or
1 flow for placebo vs. 37% TIMI grade 3 flow and 19% TIMI
grade 0 or 1 flow for tirofiban, p 5 NS for both comparisons)
(Table 4). After PTCA or DCA there was no significant
difference in the CTFC between the two groups (18.2 6 11.3
for placebo vs. 20.2 6 12.5 for tirofiban), but there was a
difference in the incidence of TIMI grade 3 flow (94% for
placebo vs. 85% for tirofiban, p , 0.001). This difference can
be accounted for by the greater incidence of TIMI grade 2 fast
flow (minimally delayed flow) in the tirofiban group (4% for
placebo vs. 14% for tirofiban, p , 0.001) such that when TIMI
grade 2 fast flow was combined with TIMI grade 3 flow, there
Table 4. Flow Data: RESTORE Angiographic Substudy
Placebo Group
(n 5 205)
Tirofiban Group
(n 5 212) p Value
Initial Procedure
Pretreatment TIMI grade 3 flow 83 (41%) 77 (37%) 0.42
Pretreatment CTFC 47.8 6 33.0 52.0 6 34.5 0.25
Posttreatment TIMI grade 3 flow
(normal flow)
189 (94%) 178 (85%) , 0.001
Posttreatment TIMI grade 2 fast
flow (minimally delayed flow)
8 (4%) 29 (14%) , 0.001
Posttreatment TIMI grade 2 fast
flow/grade 3 flow (combined)
197 (98%) 207 (99%) 0.41
Posttreatment CTFC 18.2 6 11.3 20.2 6 12.5 0.17
Follow-Up Angiography
6-mo follow-up TIMI grade 3 flow 129 (64%) 129 (62%) 0.69
6-mo follow-up CTFC 37.5 6 28.5 37.0 6 28.7 0.87
Change in CTFC
Pretreatment–posttreatment 28.1 6 32.0 30.1 6 34.4 0.62
Follow-up–posttreatment 18.5 6 30.3 16.1 6 27.8 0.51
Pretreatment–follow-up 12.0 6 36.9 14.2 6 35.4 0.6
Data presented are mean value 6 SD or number (%) of patients. CTFC 5
corrected Thrombolysis in Myocardial Infarction (TIMI) frame count.
Table 2. Six-Month End Points: RESTORE Angiographic Substudy
Placebo Group
(n 5 1,069)
[no. (%) of pts]
Tirofiban Group
(n 5 1,070)
[no. (%) of pts]
Risk
Reduction p Value
Composite
end point 290 (27.1%) 258 (24.1%) 11% 0.11
Death 15 (1.4%) 19 (1.8%) NA 0.49
MI 81 (7.6%) 67 (6.3%) 17% 0.23
Procedure
Repeat PTCA 183 (17.1%) 168 (15.7%) 8% 0.36
CABG 73 (6.8%) 59 (5.5%) 9% 0.21
Stent for abrupt
closure
27 (2.5%) 16 (1.5%) 40% 0.09
CABG 5 coronary artery bypass graft surgery; pts 5 patients; other
abbreviations as in Table 1.
Table 3. Initial Angiographic and Procedural Characteristics:
RESTORE Angiographic Substudy
Placebo Group
(n 5 205)
Tirofiban Group
(n 5 212) p Value
Target vessel
LAD 74 (36%) 86 (41%) 0.37
LCx 44 (21%) 41 (19%) 0.63
RCA 71 (35%) 73 (34%) 0.98
Other 16 (8%) 12 (6%) 0.44
Before procedure
Ref diam (mm) 2.70 6 0.57 2.77 6 0.74 0.27
MLD (mm) 0.54 6 0.33 0.57 6 0.39 0.39
% DS (%) 80.5 6 11.5 79.3 6 13.3 0.36
After procedure
Ref diam (mm) 2.66 6 0.57 2.74 6 0.72 0.23
MLD (mm) 1.89 6 0.48 1.89 6 0.56 0.96
Acute gain (mm) 1.35 6 0.51 1.32 6 0.55 0.57
Residual stenosis (%) 28.1 6 10.4 29.8 6 12.0 0.15
Data presented are number (%) of patients or mean value 6 SD. DS 5
diameter stenosis; LAD 5 left anterior descending coronary artery; LCx 5 left
circumflex coronary artery; MLD 5 minimal lumen diameter; RCA 5 right
coronary artery; Ref diam 5 reference diameter.
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was no significant difference between the two groups (98% for
placebo vs. 99% for tirofiban, p 5 NS). There were no
significant differences between groups in TIMI grade 0 or 1
flow (0.5% for placebo vs. 0.0% for tirofiban, p 5 NS) or TIMI
grade 2 slow flow (markedly delayed flow) (2% vs. 1%,
respectively, p 5 NS). Moreover, there was no difference in the
change in CTFC from before to after angioplasty between the
two groups (28.1 6 32.0 for placebo vs. 30.1 6 34.4 for
tirofiban, p 5 NS).
There was no difference between the tirofiban and placebo
groups when 6-month restenosis was defined in a number of
ways (Table 5). A $50% loss of lumen diameter gained after
the initial procedure occurred in 50% of both the placebo and
tirofiban groups (p 5 0.99). A $50% stenosis at the time of
follow-up angiography was present in 57% (n 5 193) of the
arteries in the placebo group and in 51% (n 5 196, p 5 0.26)
of those in the tirofiban group (only arteries with ,50%
stenosis at the initial postprocedural angiographic analysis
were included in this analysis). A minimal lumen diameter loss
$0.72 mm was present in 44% of arteries in the placebo group
and in 42% of those in the tirofiban group (p 5 0.69). The late
loss for tirofiban-treated patients did not differ from that of
placebo-treated patients (0.67 6 0.72 mm vs. 0.70 6 0.73 mm,
p 5 NS), and likewise, the loss index (late loss divided by acute
gain) for tirofiban-treated patients did not differ from that of
placebo-treated patients (0.50 6 0.57 vs. 0.51 6 0.58, p 5 NS).
Figure 1 shows virtually superimposable cumulative distribu-
tion functions for the minimum lumen diameters before and
after PTCA and at follow-up. Patients with angiographic
thrombus (TIMI flow grades 2 to 4) (28) were not found to
have a higher risk of restenosis than patients without angio-
graphically apparent thrombus (54% vs. 56%, respectively, p 5
NS).
Discussion
Acute coronary artery occlusion and delayed restenosis
remain major limitations of percutaneous coronary revascular-
ization. Recently, the RESTORE study group reported (23)
that a 36-h infusion of tirofiban reduced the relative incidence
of the prespecified composite end point of adverse cardiac
outcomes by 38% (3.3% absolute reduction) at 2 days (p ,
0.005), and by 27% at 7 days (2.8% absolute reduction) (p 5
0.02). However, by 30 days the relative risk reduction de-
creased to 16% (1.9% absolute reduction) and was not statis-
tically significant (23). Although the 3% absolute reduction in
the incidence of the composite end point at 6 months (27.1%
placebo vs. 24.1% tirofiban) was similar to that previously
reported at 2 days (8.7% vs. 5.4%, p , 0.005), this 11% relative
reduction in the composite end point did not reach statistical
significance (p 5 0.11). These benefits were obtained without
a significant increase in thrombocytopenia or major bleeding
complications in the tirofiban group versus the placebo-treated
group (23).
It could be hypothesized that residual thrombus at the
completion of an intervention may form a nidus for cellular
organization and may contribute in part to the risk of resten-
osis. However, in the present study patients with angiographi-
cally apparent thrombus were not found to have a higher risk
of restenosis than patients without thrombus (54% vs. 56%).
There was also no difference in clinical restenosis between the
tirofiban and placebo groups. The 3% absolute reduction in
the composite end point was achieved early and was already
apparent at 2 days. The cumulative event curves remained
relatively parallel beyond this time point out to 6 months (Fig.
2). Moreover, in the present, and to our knowledge the first,
angiographic substudy to be reported for a GP IIb/IIIa inhib-
itor, we found that tirofiban did not reduce the incidence of
angiographic restenosis when defined in a number of ways.
There was no significant difference in the number of arteries
with $50% stenosis, $50% loss of lumen diameter gained or
$0.72-mm loss of lumen diameter between the two groups.
Likewise, there was no difference in either the late loss or the
loss index between the tirofiban and placebo groups. Indeed,
Figure 2 shows virtually superimposable cumulative distribu-
tion functions for the minimum lumen diameters before and
after PTCA and at follow-up.
Table 5. Six-Month Follow-Up: RESTORE Angiographic Substudy
Placebo Group
(n 5 205)
Tirofiban Group
(n 5 212) p Value
MLD (mm) 1.19 6 0.68 1.22 6 0.71 0.62
$50% loss of gain 102 (50%) 105 (50%) 0.96
% DS $50%* 110 (57%) 100 (51%) 0.2
Loss $0.72 (mm) 90 (44%) 88 (42%) 0.69
Late loss (mm) 0.70 6 0.73 0.67 6 0.72 0.67
Loss index 0.51 6 0.58 0.50 6 0.57 0.88
*Requires initial post–coronary angioplasty stenosis ,50% (193 for placebo,
196 for tirofiban). Data presented are mean value 6 SD or number (%) of
patients. Abbreviations as in Table 3.
Figure 1. Cumulative distribution functions of minimal lumen diam-
eters before and after intervention and at 6 months of follow-up for
tirofiban- and placebo-treated patients. As can be seen, the cumulative
distribution functions do not differ significantly between the treatment
groups and are nearly superimposible at all time points.
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Previous reports. Previous reports have suggested (15) that
abciximab, an antibody with a longer duration of action and
other potential non GP IIb/IIIa receptor blocking activities,
may reduce the incidence of clinical restenosis. The Evaluation
of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing
Ischemic Complications (EPIC) trial (15) of abciximab in high
risk patients undergoing angioplasty reported a 26% decrease
in repeat target vessel revascularization at 6 months. An
angiographic substudy was not performed in that trial to assess
restenosis rates. This effect of abciximab was not reproduced in
two subsequent trials of angioplasty in patients with refractory
unstable angina (Chimeric c7E3 Antiplatelet Therapy in Un-
stable Angina Refractory to Standard Treatment [CAPTURE]
trial [30]) at lower risk (Evaluation of PTCA to Improve
Long-Term Outcome by c7E3 GPIIb/IIIa Receptor Blockade
[EPILOG] trial [31]). In the CAPTURE trial, when abciximab
was infused predominantly before PTCA, there was no differ-
ence in death, myocardial infarction or repeat revasculariza-
tion at 6 months between abciximab- and placebo-treated
patients. In the EPILOG trial, a 3% absolute difference was
evident in this composite end point between abciximab- and
placebo-treated patients, similar to that observed in the
RESTORE trial. There was no difference in the rates of repeat
revascularization. No angiographic follow-up data have yet
been reported from the EPILOG trial. In the only other
large-scale trial of GPIIb/IIIa inhibitor in PTCA, the Integrelin
to Manage Platelet Aggregation to Combat Thrombosis
(IMPACT) II trial of Integrilin (eptifibatide) (32), the absolute
reduction in composite end point seen at 30 days (2.2%, low
dose eptifibatide vs. placebo) persisted at 6 months but was not
statistically significant.
Study limitation. The main limitation of this study was the
relatively low rate of follow-up angiography (67%) in the
angiographic substudy. That the substudy cohort was enriched
with symptomatic patients may account, in part, for the
relatively high rates of restenosis that were observed. None-
theless, the angiographic substudy cohort was representative of
the overall study group, and there was no difference in
follow-up rates between the two treatment groups. Thus, the
low rate of angiographic follow-up is unlikely to have been a
source of treatment bias.
Conclusions. Six-month follow-up of patients undergoing
high risk PTCA or DCA in the RESTORE trial demonstrated
no significant benefit of tirofiban in reducing the composite
clinical end point of death, myocardial infarction, CABG or
repeat PTCA of the target vessel. The 3% absolute reduction
in this composite end point that was observed within 48 h of
initial treatment persisted over the 6-month follow-up period,
but there was no evidence of additional late clinical benefit.
Angiographic follow-up of a subset of patients demonstrated
that tirofiban did not reduce angiographic restenosis.
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